A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001

Inclusion Criteria

• •Be male or female adults, 18 years of age or older
• •Have SBS that is inadequately controlled on current antidiarrheal medication (e.g., loperamide or diphenoxylate), including subjects with ileostomies
• •Must have been deemed a completer of study protocol MP-101-CL-001.
• •Males or non-pregnant, non-lactating females who are postmenopausal, naturally or surgically sterile, or who agree to use effective contraceptive methods throughout the course of the study. Postmenopausal is defined as at least 12 months of natural spontaneous amenorrhea, or at least 6 weeks following surgical menopause (bilateral oophorectomy)
• •Females of childbearing potential must agree to use 1 of the following acceptable birth control methods:
• •* Surgically sterile (hysterectomy or bilateral oophorectomy)
• •* Surgically sterile (bilateral tubal ligation with surgery at least 6 weeks prior to study initiation)
• •* Intrauterine device (IUD) in place for at least 3 months
• •* Abstinence (not having sexual intercourse)
• •* Barrier method (condom or diaphragm) with spermicide for at least 14 days prior to screening and through study completion
• •* Stable hormonal contraceptive for at least 3 months prior to study and through study completion
• •* Vasectomized partner
• •Females of childbearing potential must have a negative serum human chorionic gonadotropin (hCG) pregnancy test at Visit 1.
• •Be able to understand and provide signed informed consent